0001127602-17-024713.txt : 20170802 0001127602-17-024713.hdr.sgml : 20170802 20170802150024 ACCESSION NUMBER: 0001127602-17-024713 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lerman Bradley E CENTRAL INDEX KEY: 0001559405 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 17999532 MAIL ADDRESS: STREET 1: MEDTRONIC, INC. STREET 2: 710 MEDTRONIC PKWY MSLC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0424 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-07-31 0001613103 Medtronic plc MDT 0001559405 Lerman Bradley E 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 1 SVP General Counsel & Corp Sec Ordinary Shares 2017-07-31 4 A 0 11910 0 A 59960 D Stock Option (Right to Buy) 83.97 2017-07-31 4 A 0 47637 0 A 2018-07-31 2027-07-31 Ordinary Shares 47637 47637 D Stock Option (Right to Buy) 83.97 2017-07-31 4 A 0 1191 0 A 2018-07-31 2027-07-31 Ordinary Shares 1191 1191 D The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. /s/ Rhonda L. Ingalsbe, Attorney-in-fact 2017-08-01